Biotech companies see China as one of the biggest healthcare opportunities, but would need partnerships before approaching the market, a new report suggests.
Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.